Table 1 Patient characteristics and summary of clinical assessments at baseline (B) and follow-up (F)
Subject | Age | Gender | Disease duration (months) | ILAR Subtype & Systemic Medication | Active joint count | Clinician assessed disease activity in injected knee (Y/N) | JADAS10 | cJADAS10 | ESR | CHAQ | Pain global score (cm) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | B | F | B | F | B | F | B | F | B | F | B | F | B | F |
1 | 12.3 | F | 0 | psoriatic m | 1lk | 1lk | Y | Y | n/a | 5.5 | 9.3 | 5.5 | n/a | 10 | 1.4 | n/a | 6.1 | 4.0 |
2 | 7.7 | F | 27 | per oligo m | 2rk,ra | – | Y | – | 7.0 | – | 7.0 | – | 20 | – | 0.3 | – | 3.2 | – |
3 | 16.0 | F | 8 | per oligo z | 2lk,rk | 0 | Y | N | 8.4 | 0.0 | 7.8 | 0.0 | 26 | 16 | 0.5 | 0 | 3.3 | 0.0 |
4 | 11.6 | M | 140 | per oligo | 1rk | 1rk | Y | Y | 4.2 | 2.0 | 4.2 | 2.0 | 5 | 2 | 1.0 | 0 | 3.6 | 0.0 |
5 | 13.4 | M | 53 | ext oligo | 1lk | 1rk | Y | N | 7.1 | n/a | 7.1 | 3.0 | 2 | n/a | 0.0 | 0 | 3.0 | 1.5 |
6 | 16.2 | F | 6 | RF+ poly m,d | 2lk,rk | 0 | Y | N | 7.2 | 0.0 | 7.2 | 0.0 | 5 | 5 | 1.0 | 0.3 | 2.9 | 0.9 |
7 | 13.6 | F | 54 | per oligo d | 2lk,rk | 0 | Y | N | 12.4 | 0.0 | 11.0 | 0.0 | 34 | 15 | 0.5 | 0 | 6.3 | 0.0 |
8 | 8.1 | M | 0 | per oligo | 2lk,rk | 2rk,ra | Y | Y | 18.8 | 8.9 | 15.6 | 8.9 | 52 | 9 | 1.9 | 1.9 | 10.0 | 6.8 |
9 | 13.4 | M | 74 | ext oligo d | 2lk,rk | 0 | Y | N | 10.8 | 1.2 | 10.0 | 1.2 | 28 | 15 | 1.3 | n/a | 6.5 | 6.1 |
10 | 15.3 | F | 92 | RF- poly | 1rk | 0 | Y | N | 9.2 | n/a | 9.2 | 4.2 | 16 | n/a | 1.3 | n/a | 7.1 | 3.4 |
11 | 14.3 | M | 14 | per oligo | 1rk | 0 | Y | N | 2.0 | 0.0 | 2.0 | 0.0 | 2 | 5 | 0.0 | n/a | 0.0 | 0.0 |
Median | 13.4 |  | 27 |  | 1.5 | 0.0†|  |  | – | – | 8.5 | 1.6* | – | – | – | – | 4.9 | 1.2$ |
IQR | 2.8 |  | 57 |  | 1.0 | 1.0 |  |  | – | – | 2.7 | 3.9 | – | – | – | – | 3.4 | 3.9 |